Drugs / CYT006-AngQb
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00500786 | Nov 2004 → Sep 2006 | essential hypertension | Cytos Biotechnology AG | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00710372 | Jun 2008 → Jul 2009 | essential hypertension | Cytos Biotechnology AG | Completed | No outcome recorded |
| Phase 2 | NCT00701649 | Mar 2008 → Mar 2009 | essential hypertension | Cytos Biotechnology AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYT006-AngQb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00500786 ↗ |
| Modality | Vaccine | “CYT006-AngQb-a vaccine based on a virus-like particle” PMID 18328929 ↗ Mar 2008 |
| Route | Subcutaneous | “receive subcutaneous injections of either 100 mug CYT006-AngQb” PMID 18328929 ↗ Mar 2008 |